Structure for peptidase M10.002: matrix metallopeptidase-8

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

PDB	Organism	Resolution	Comment
1KBC	Homo sapiens	1.81 Å	complex with 3-formyl-2-hydroxy-5-methyl-hexanoic acid hydroxyamide
The catalytic zinc is shown as a light grey CPK sphere. Structural calcium ions are shown as yellow CPK spheres. The zinc ligands are shown in ball-and-stick representation: His217, His221 and His227 in purple. The catalytic Glu218 is shown in blue. Bound inhibitor is shown in grey in ball-and-stick representation.

		Show surface

TERTIARY STRUCTURE DATA
Comment	Resolution	PDB	PDBe	SCOP	CATH	PDBSum	Proteopedia	Reference
Homo sapiens
complex with malonic and asparagine based inhibitor	2.00 Å	1A85	1A85	1A85	1A85	1A85	1A85	Brandstetter et al., 1998
complex with malonic and aspartate based inhibitor	2.00 Å	1A86	1A86	1A86	1A86	1A86	1A86	Brandstetter et al., 1998
complex with HMR2909 inhibitor.	1.70 Å	1BZS	1BZS	1BZS	1BZS	1BZS	1BZS	Matter et al., 1999
catalytic domain; complex with Pro-Leu-L-Trp phosphonate	1.40 Å	1I73	1I73	1I73	1I73	1I73	1I73	Gavuzzo et al., 2000
catalytic domain; complex with 2-(biphenyl-4-sulfonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid	1.20 Å	1I76	1I76	1I76	1I76	1I76	1I76	Gavuzzo et al., 2000
catalytic domain; complex with Pro-Leu-Gly-hydroxylamine	2.50 Å	1JAN	1JAN	1JAN	1JAN	1JAN	1JAN	Reinemer et al., 1994
catalytic domain; complex with 3-mercapto-2-benzylpropanoyl-Ala-Gly-NH2	2.40 Å	1JAO	1JAO	1JAO	1JAO	1JAO	1JAO	Grams et al., 1995
catalytic domain; complex with Pro-Leu-Gly-hydroxylamine	1.82 Å	1JAP	1JAP	1JAP	1JAP	1JAP	1JAP	Bode et al., 1994
catalytic domain; complex with 1-hydroxylamine-2-isobutylmalonyl-Ala-Gly-NH2	2.25 Å	1JAQ	1JAQ	1JAQ	1JAQ	1JAQ	1JAQ	Grams et al., 1995
complex with but-3-enyl-[5-(4-chloro-phenyl)-3,6-dihydro-[1,3,4]thiadiazin-2-ylidene]-amine	2.70 Å	1JH1	1JH1	1JH1	1JH1	1JH1	1JH1	Schroder et al., 2001
complex with barbiturate	2.00 Å	1JJ9	1JJ9	1JJ9	1JJ9	1JJ9	1JJ9	Brandstetter et al., 2001
complex with 3-formyl-2-hydroxy-5-methyl-hexanoic acid hydroxyamide	1.81 Å	1KBC	1KBC	1KBC	1KBC	1KBC	1KBC	Betz et al., 1997
catalytic domain; complex with BB94	2.10 Å	1MMB	1MMB	1MMB	1MMB	1MMB	1MMB	Grams et al., 1995
catalytic domain	2.10 Å	1MNC	1MNC	1MNC	1MNC	1MNC	1MNC	Stams et al., 1994
complex with N-2-[(4'-cyano-1,1'-biphenyl-4-yl)oxy]ethyl-N'-hydroxy-N-methylurea	1.80 Å	1ZP5	1ZP5	1ZP5	1ZP5	1ZP5	1ZP5	Campestre et al., 2006
complex with phosphonate inhibitor (S-enantiomer) (1S)-1-[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino-2-methylpropylphosphonic acid	1.56 Å	1ZS0	1ZS0	1ZS0	1ZS0	1ZS0	1ZS0	Pochetti et al., 2006
complex with phosphonate inhibitor (1R)-1-[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino-2-methylpropylphosphonic acid	1.87 Å	1ZVX	1ZVX	1ZVX	1ZVX	1ZVX	1ZVX	Pochetti et al., 2006
complex with peptide IAG	1.50 Å	2OY2	2OY2	2OY2	2OY2	2OY2	2OY2	Bertini et al., 2006
uninhibited human mmp-8	1.70 Å	2OY4	2OY4	2OY4	2OY4	2OY4	2OY4	Bertini et al., 2006
complex with (5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo- 3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]- 3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine- 2-carboxamide	2.00 Å	3DNG	3DNG	3DNG	3DNG	3DNG	3DNG	Morales et al., 2004
complex with N-[2-(2-amino-3,4-dioxocyclobut-1-en-1-yl)- 1,2,3,4-tetrahydroisoquinolin-7-yl]methyl- 4-oxo-3,5,6,8-tetrahydro-4H-thiopyrano[4',3':4,5]thieno[2,3- d]pyrimidine-2-carboxamide 7,7-dioxide	1.60 Å	3DPE	3DPE	3DPE	3DPE	3DPE	3DPE	Morales et al., 2004
complex with N-[2-(2-amino-3,4-dioxocyclobut-1-en-1-yl)- 1,2,3,4-tetrahydroisoquinolin-7-yl]methyl- 4-oxo-3,5,6,8-tetrahydro-4H-thiopyrano[4',3':4,5]thieno[2,3- d]pyrimidine-2-carboxamide 7,7-dioxide	2.10 Å	3DPF	3DPF	3DPF	3DPF	3DPF	3DPF	Morales et al., 2004
mature peptidase	1.88 Å	3TT4	3TT4	3TT4	3TT4	3TT4	3TT4	Devel et al., 2012
mature peptidase	1.20 Å	4QKZ	4QKZ	4QKZ	4QKZ	4QKZ	4QKZ
complex with bf471 (catechol inhibitor)	1.30 Å	5H8X	5H8X	5H8X	5H8X	5H8X	5H8X